Trials / Completed
CompletedNCT05305677
Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome
Effect of NMN (Nicotinamide Mononucleotide) Intervention on Patients With Polycystic Ovary Syndrome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Peking University Third Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to understand the effect of Nicotinamide mononucleotide (NMN) on patients with polycystic ovary syndrome.
Detailed description
This study aims to evaluate the effects of NMN on reproductive endocrine and metabolism, chronic inflammation, and reproductive outcomes in women with polycystic ovary syndrome (PCOS), and to explore its underlying mechanisms to provide the intervention strategies for PCOS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | NMN intervention | NMN capsules (total of 600mg/day) for 8 weeks |
| OTHER | Placebo | NMN-free placebo capsules for 8 weeks |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2022-03-31
- Last updated
- 2025-11-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05305677. Inclusion in this directory is not an endorsement.